Drug intelligence / Profile preview

PSM101

Development stage: Preclinical
Lead developer: PrecisemAb Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

PSM101 is an investigational **antibody-drug conjugate (ADC)** developed by PrecisemAb Biotech Co., Ltd for the treatment of **neoplasms**, with active indications in **head and neck neoplasms** and **colonic cancer** (colorectal cancer). It features proprietary Lock-ADC technology designed for higher masking ability, low immunogenicity, prevention of anti-drug antibody binding, and prolonged serum half-life. As of August 2025, its global highest R&D status remains **preclinical**, with plans to complete stable cell clone generation in 2023 and non-human primate safety testing in early 2024.[1][3]

Other names: Lock-ADC

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on PSM101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSM101.

Explore the full profile